Vandenput Liesbeth, Labrie Fernand, Mellström Dan, Swanson Charlotte, Knutsson Thomas, Peeker Ralph, Ljunggren Osten, Orwoll Eric, Eriksson Anna L, Damber Jan-Erik, Ohlsson Claes
Center for Bone Research, Departments of Internal Medicine and Geriatrics, The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden.
J Bone Miner Res. 2007 Feb;22(2):220-7. doi: 10.1359/jbmr.061018.
Androgens are important regulators of bone and prostate health in elderly men. The role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in men is unclear. We show that specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men.
Androgens are important regulators of bone and prostate health in elderly men. Local synthesis and degradation of androgens are likely to be important parameters of biological action of androgens in androgen-responsive tissues. The aim of this study was to determine the role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in elderly men.
A subsample of the population-based Swedish part of the MrOS study (n = 631, average age = 75.9 years) was investigated. Bone parameters were measured using DXA. Serum levels of total testosterone (T) and dihydrotestosterone (DHT) were measured by gas chromatography/mass spectroscopy (GC-MS); androstane-3alpha,17beta-diol-3glucuronide (3G) and androstane-3alpha,17beta-diol-17glucuronide (17G) were measured by liquid chromatography/mass spectroscopy. Prostate volume (n = 159) was measured by transrectal ultrasound.
The general pattern is that two of the glucuronidated androgen metabolites, namely 17G and 3G, are stronger positive predictors of BMD than the bioactive androgens (T and DHT). In addition, 17G is a clear positive predictor of prostate volume, explaining 4.5% of the variance in prostate volume, whereas the bioactive androgens do not display any association with prostate volume.
Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Future studies should determine if the glucuronidated androgen metabolites also reflect other biological correlates of androgenic activity, including prostate cancer, and if low levels might be a marker of general androgen deficiency in men.
雄激素是老年男性骨骼和前列腺健康的重要调节因子。血清中葡萄糖醛酸化雄激素代谢物水平作为男性骨密度（BMD）和前列腺体积预测指标的作用尚不清楚。我们发现特定的葡萄糖醛酸化雄激素代谢物可预测老年男性的骨密度和前列腺体积。
雄激素是老年男性骨骼和前列腺健康的重要调节因子。雄激素在雄激素反应性组织中的局部合成和降解可能是雄激素生物学作用的重要参数。本研究的目的是确定血清中葡萄糖醛酸化雄激素代谢物水平作为老年男性骨密度和前列腺体积预测指标的作用。
对基于人群的瑞典MrOS研究中的一个子样本（n = 631，平均年龄 = 75.9岁）进行了调查。使用双能X线吸收法（DXA）测量骨参数。通过气相色谱/质谱法（GC-MS）测量总睾酮（T）和双氢睾酮（DHT）的血清水平；通过液相色谱/质谱法测量雄烷-3α,17β-二醇-3-葡萄糖醛酸苷（3G）和雄烷-3α,17β-二醇-17-葡萄糖醛酸苷（17G）。通过经直肠超声测量前列腺体积（n = 159）。
总体模式是，两种葡萄糖醛酸化雄激素代谢物，即17G和3G，比生物活性雄激素（T和DHT）更能作为骨密度的强阳性预测指标。此外，17G是前列腺体积的明确阳性预测指标，可解释前列腺体积变异的4.5%，而生物活性雄激素与前列腺体积无任何关联。
血清中特定葡萄糖醛酸化雄激素代谢物水平可预测老年男性的骨密度和前列腺体积。未来的研究应确定葡萄糖醛酸化雄激素代谢物是否也反映雄激素活性的其他生物学关联，包括前列腺癌，以及低水平是否可能是男性总体雄激素缺乏的标志物。
